Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. On August 15, 2008 the U.S. Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease (HD), the first in the US. The compound has been known since the 1950s. The effort for US FDA approval was led by Dr. Joseph Jankovic. According to a 2008 news report, "Americans with Huntington's who weren't Jankovic's patients ordered tetrabenazine from Canada if they could afford it...